24 results
8-K
EX-99.1
slueqzosm8nxdhlp76rc
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
7zzl02xf2q 9o14y5y
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
S-3
EX-1.2
k3w8b80
4 Nov 21
Shelf registration
4:59pm
S-3
EX-4.4
1m26eqw8y
4 Nov 21
Shelf registration
4:59pm
S-3
EX-4.3
lqzwy56 onod
4 Nov 21
Shelf registration
4:59pm
10-K
ehlm6
29 Mar 21
Annual report
6:03am
10-K
EX-10.2
a14dqof8vh
29 Mar 21
Annual report
6:03am
10-Q
qywbu0tu
11 Dec 20
Quarterly report
7:30am
424B4
ygqdvge
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1/A
6477pbe8xwhzqw9ddnq6
22 Oct 20
IPO registration (amended)
6:13am
S-1/A
EX-1.1
r5x8pfu2
22 Oct 20
IPO registration (amended)
6:13am
S-1/A
EX-4.2
phq8966188b
22 Oct 20
IPO registration (amended)
6:13am
CORRESP
lgon4b999qx7ukat026y
13 Oct 20
Correspondence with SEC
12:00am